Argenx shrugs off myasthenia gravis threat from UCB as Vyvgart nears next potential launch
Argenx shrugs off myasthenia gravis threat from UCB as Vyvgart nears next potential launch fkansteiner Thu, 05/09/2024 - 16:40
Argenx shrugs off myasthenia gravis threat from UCB as Vyvgart nears next potential launch fkansteiner Thu, 05/09/2024 - 16:40
Pfizer puts 74 Swiss jobs on chopping block as it folds Seagen into its cancer operations fkansteiner Thu, 05/09/2024 - 11:36
As Vyvanse generics bite, Takeda sets out on $900M restructuring plan zbecker Thu, 05/09/2024 - 11:28
In gene therapy race, bluebird leads Vertex in activating treatment centers but trails in patient starts kdunleavy Thu, 05/09/2024 - 11:15
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer fkansteiner Thu, 05/09/2024 - 10:45
US gene therapy approvals create a big problem for Brazil. Regulators have to come together, FDA's Peter Marks says aarmstrong Thu, 05/09/2024 - 10:17
Industry's sudden decoupling from Chinese CDMOs could harm millions of patients, BIO warns lawmakers aliu Thu, 05/09/2024 - 09:21
Opportunities & Challenges of Digital Pathology Adoption in CDx Development lpastoria Thu, 05/09/2024 - 09:18